Chemotherapy for gastric cancer

doi:10.3748/wjg.v12.i2.204

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 2

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4722)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-4) series.

Item

Count

PDF

540

HTML

3921

Tables (1-4)

261

Sum=4722

Jan 14, 2006 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (71)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jan 14, 2006; 12(2): 204-213
Published online Jan 14, 2006. doi: 10.3748/wjg.v12.i2.204

Table 1 Single agent activity in advanced gastric cancer

Agents	Response rate (%)
Mitomycin C	30
Doxorubicin	17
Epirubicin	19
Cisplatin	19
BCNU	18
5-Fluorouracil	21
Etoposide (oral)	21
Hydroxurea	19
UFT	27
Capecitabina	19
S-1	45
Paclitaxel	17-23
Docetaxel	17-29
CPT-11	18

Table 2 Combination therapy for advanced gastric cancer

	Response rat (%)	Median survival (mo)
FU-based combinations
FAM	30-42	6-9
FAMTX	33-63	6
ELF	53	11
Modified-ELF	16-42	6-9.5
Cisplatin-5-FU CI synergism
PF	40	9-10
ECF	59-71	8.7
P-5-FU 48-h CI	50	9.3
P-5FU 24-h CI	58	11
Cisplatin-based combinations
EAP	33-64	9
FLEP	35	8
FLEP-type	39	11
LV5FU2-P	27	13.3
Combinations including new drugs
P-CPT11	41-58	9-12
LOHP-CPT11	50	8.5
CPT11-bolus 5-FU	22	7.6
CPT11- 5-FU CI	20	7
P-Xeloda	54.8	10.1
ECC	59	9.6
P-S-1	73-74	12
TPFU/LV	50	11-14
DP	37-56	9-11
DPF	51	9.3

CI: Continuous infusion.

Table 3 Meta-analysis of randomized trials of adjuvant cytotoxic chemotherapy in gastric cancer

Author.^Year	Number of patients/number of trials included	Mortalityrisk ratio	95% confidence interval	P value
Hermans.¹⁹⁹³	2 096/11	0.88	0.78-1.08	NS
Earle. ¹⁹⁹⁹	1 190/13	0.80	0.66-0.97	0.024
Mari. ²⁰⁰⁰	3 658/20	0.82	0.75-0.89	<0.001
Panzini.²⁰⁰²	2 913/17	0.72	0.62-0.84	NA
Janunger.²⁰⁰²	3 962/21	0.84	0.74-0.96	NA

Table 4 Phase II studies of preoperative chemotherapy in localized gastric cancer

Author.^Year	Number of patients	Neoadjuvant chemotherapy regimen	Adjuvant chemotherapy regimen	R0 rate	_PCR	Median survival (mo)	2-yr survival rate (%)
Wilke.¹⁹⁸⁹	34	EAP × 2	EAP × 2	29	5	18	26
Leichman.¹⁹⁹²	38	CF ×2	Intraperitoneal	76	3	17	NR
Ajani.¹⁹⁹³	48	EAP × 3	EAP × 2	77	0	16	42
Kang.¹⁹⁹⁶	53	EFP ×2-3	EFP × 3-6	71	4	43	NR
	54	Surgery	None	61		30	NR
Crookes.¹⁹⁹⁷	59	CF ×2	Intraperitoneal	71	5	48	64
Songun.¹⁹⁹⁹	27	FAMtx × 4	None	56	0	36	62
	29	Surgery	None	62		13.1	NR

EAP: etoposide, doxorubicin and cisplatin; CF: cisplatin and 5-fluoruracil; EFP: etoposide, 5-fluouracil and cisplatin; FAMtx: 5-fluoruracil, doxorubicin and methotrexate; pCR: pathological complete remission; NR: no reported

Citation: Sastre J, García-Saenz JA, Díaz-Rubio E. Chemotherapy for gastric cancer. World J Gastroenterol 2006; 12(2): 204-213
URL: https://www.wjgnet.com/1007-9327/full/v12/i2/204.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i2.204